Brand name: In-111 Zevalin
Ibritumomab is a medicine to treat non-Hodgkin lymphoma when other medicines do not help or it has developed. It may be combined with rituximab and In-111/ Y-90 (radioactive materials).
Ibritumomab refers to monoclonal antibody proteins. It binds to the cells causing non-Hodgkin lymphoma. It is used together with radioactive materials. Radioactive material In-111 confirms the access to the cells has been received. Radioactive material Y-90 destroys the cells, thus helping to decrease the quantity of abnormal cells affected by non-Hodgkin lymphoma.